Distinct roles for PARP-1 and PARP-2 in c-Myc–driven B-cell lymphoma in mice

• Published in: Blood Vol. 139; no. 2; pp. 228 - 239
• Main Authors: Galindo-Campos, Miguel A., Lutfi, Nura, Bonnin, Sarah, Martínez, Carlos, Velasco-Hernandez, Talia, García-Hernández, Violeta, Martín-Caballero, Juan, Ampurdanés, Coral, Gimeno, Ramón, Colomo, Lluis, Roué, Gaël, Guilbaud, Guillaume, Dantzer, Françoise, Navarro, Pilar, Murga, Matilde, Fernández-Capetillo, Oscar, Bigas, Anna, Menéndez, Pablo, Sale, Julian E., Yélamos, José
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 13.01.2022; American Society of Hematology
• Subjects: Animals; Cancer; Carcinogenesis - genetics; Cellular Biology; DNA Damage; Gene Deletion; Gene Expression Regulation, Neoplastic; Hematology; Human health and pathology; Life Sciences; Lymphoma, B-Cell - genetics; Medicin och hälsovetenskap; Mice; Mice, Knockout; Poly (ADP-Ribose) Polymerase-1 - genetics; Poly(ADP-ribose) Polymerases - genetics; Proto-Oncogene Proteins c-myc - genetics; Subcellular Processes
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood.2021012805

Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc–driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc–driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc–driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc–driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc–driven tumors. •PARP-2 deficiency prevents c-Myc–driven B-cell lymphoma progression, whereas PARP-1 deficiency accelerates lymphomagenesis.•PARP-2 limits replication stress of c-Myc–overexpressing B cells and promotes cell survival, whereas PARP-1 affects regulatory T cells. [Display omitted]